ZBIO Zenas BioPharma, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
19:19
Feb 04
Feb 04
Short ZBIO — LLY's mAb being nondepleting is a negative clinical/competitive readthrough.
Short ZBIO — LLY's mAb being nondepleting is a negative clinical/competitive readthrough, implying ZBIO's approach or thesis is disadvantaged by this mechanism finding.
MED
11:59
Jan 06
Jan 06
ZBIO's inferior construct and poor results make it unattractive
The author argues ZBIO's CD19 autoimmune drug is weak because it inhibits rather than depletes B cells, and its IgG4-RD results were much worse than Uplizna's, so it is no longer a competitive threat.
HIGH
About ZBIO Investor Commentary
Across the available history and selected sources, Buzzberg tracks ZBIO (Zenas BioPharma, Inc.) across 2 sources: 0 bullish vs 1 bearish calls from 2 authors. Historical directional balance: -50% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 2 total trade ideas tracked. Latest voices: A May MD, u/IJesusChrist.